Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.
作者： Marlo Blazer , Christina Wu , Richard M. Goldberg , Gary Phillips , Carl Schmidt
DOI: 10.1245/S10434-014-4225-1
关键词:
摘要: Background For patients with metastatic pancreatic cancer, FOLFIRINOX (fluorouracil [5-FU], leucovorin [LV], irinotecan [IRI], and oxaliplatin) has shown improved survival rates compared gemcitabine but significant toxicity, particularly in a high tumor burden. Because of reported response exceeding 30 %, the authors began to use modified (m) regimen for advanced nonmetastatic disease aimed at downstaging resection. This report describes their experience mFOLFIRINOX aggressive surgical
springer.com
elsevier.com
sci-hub.se 参考文章(17)
Edward J. Kim, Edgar Ben-Josef, Joseph M. Herman, Tanios Bekaii-Saab, Laura A. Dawson, Kent A. Griffith, Isaac R. Francis, Joel K. Greenson, Diane M. Simeone, Theodore S. Lawrence, Daniel Laheru, Christopher L. Wolfgang, Terence Williams, Mark Bloomston, Malcolm J. Moore, Alice Wei, Mark M. Zalupski, A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer Cancer. ,vol. 119, pp. 2692- 2700 ,(2013) , 10.1002/CNCR.28117
J??rg Kleeff, Carolin Reiser, Ulf Hinz, Jeannine Bachmann, J??rgen Debus, Dirk Jaeger, Helmut Friess, Markus W. B??chler, Surgery for recurrent pancreatic ductal adenocarcinoma. Annals of Surgery. ,vol. 245, pp. 566- 572 ,(2007) , 10.1097/01.SLA.0000245845.06772.7D
Sonja Gillen, Tibor Schuster, Christian Meyer zum Büschenfelde, Helmut Friess, Jörg Kleeff, Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages PLoS Medicine. ,vol. 7, pp. e1000267- ,(2010) , 10.1371/JOURNAL.PMED.1000267
Elizabeth Poplin, Yang Feng, Jordan Berlin, Mace L. Rothenberg, Howard Hochster, Edith Mitchell, Steven Alberts, Peter O'Dwyer, Daniel Haller, Paul Catalano, David Cella, Al Bowen Benson, Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group Journal of Clinical Oncology. ,vol. 27, pp. 3778- 3785 ,(2009) , 10.1200/JCO.2008.20.9007
Mark P. Callery, Kenneth J. Chang, Elliot K. Fishman, Mark S. Talamonti, L. William Traverso, David C. Linehan, Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement Annals of Surgical Oncology. ,vol. 16, pp. 1727- 1733 ,(2009) , 10.1245/S10434-009-0408-6
James D. Murphy, Saroja Adusumilli, Kent A. Griffith, Michael E. Ray, Mark M. Zalupski, Theodore S. Lawrence, Edgar Ben-Josef, Full-Dose Gemcitabine and Concurrent Radiotherapy for Unresectable Pancreatic Cancer International Journal of Radiation Oncology Biology Physics. ,vol. 68, pp. 801- 808 ,(2007) , 10.1016/J.IJROBP.2006.12.053
Hans G. Smeenk, Luca Incrocci, Geert Kazemier, Herman van Dekken, Khe T.C. Tran, Johannes Jeekel, Casper H.J. van Eijck, Adjuvant 5-FU-based chemoradiotherapy for patients undergoing R-1/R-2 resections for pancreatic cancer. Digestive Surgery. ,vol. 22, pp. 321- 328 ,(2005) , 10.1159/000089250
Andrew H. Ko, Jeanne M. Quivey, Alan P. Venook, Emily K. Bergsland, Elizabeth Dito, Brian Schillinger, Margaret A. Tempero, A Phase II Study of Fixed-Dose Rate Gemcitabine Plus Low-Dose Cisplatin Followed by Consolidative Chemoradiation for Locally Advanced Pancreatic Cancer International Journal of Radiation Oncology Biology Physics. ,vol. 68, pp. 809- 816 ,(2007) , 10.1016/J.IJROBP.2007.01.005
Jason E. Faris, Lawrence S. Blaszkowsky, Shaunagh McDermott, Alexander R. Guimaraes, Jackie Szymonifka, Mai Anh Huynh, Cristina R. Ferrone, Jennifer A. Wargo, Jill N. Allen, Lauren E. Dias, Eunice L. Kwak, Keith D. Lillemoe, Sarah P. Thayer, Janet E. Murphy, Andrew X. Zhu, Dushyant V. Sahani, Jennifer Y. Wo, Jeffrey W. Clark, Carlos Fernandez‐del Castillo, David P. Ryan, Theodore S. Hong, FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience Oncologist. ,vol. 18, pp. 543- 548 ,(2013) , 10.1634/THEONCOLOGIST.2012-0435
Helmut Oettle, Stefan Post, Peter Neuhaus, Klaus Gellert, Jan Langrehr, Karsten Ridwelski, Harald Schramm, Joerg Fahlke, Carl Zuelke, Christof Burkart, Klaus Gutberlet, Erika Kettner, Harald Schmalenberg, Karin Weigang-Koehler, Wolf-Otto Bechstein, Marco Niedergethmann, Ingo Schmidt-Wolf, Lars Roll, Bernd Doerken, Hanno Riess, Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer JAMA. ,vol. 297, pp. 267- 277 ,(2007) , 10.1001/JAMA.297.3.267